By immunohistochemistry analysis, they found that the VISTA agonists (MH5A) can greatly reduce infiltrating T cells and suppress T cell activation in all GVHD target organs, such as the liver, spleen, kidney, and lung (2, 11). This evidence concerns the gene VSIR and graft versus host disease.